A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- Sutro Biopharma, Inc.
- Study ID
- NCT05200364
- Phase
- PHASE1
- Status
- Terminated
Conditions
- Fallopian Tube Cancer
- Ovarian Cancer
- Ovarian Carcinoma
- Ovary Cancer
- Primary Peritoneal Carcinoma
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- STRO-002 — DRUGintravenous antibody drug conjugate
- Bevacizumab — DRUGanti-VEGF agent
Study Details
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Key Dates
- First listed
- Jan 20, 2022
- Start date
- Mar 22, 2022
- Status verified
- Nov 2024
- Primary completion
- Jun 1, 2025
- Completion
- Jun 1, 2025
Study Design
- Enrollment
- 58 participants (actual)
- Allocation
- NA
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Experimental :STRO-002 treatment in combination with BevacizumabDose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg
Primary Outcome Measure
Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy [ Time Frame: From baseline through end of study (approximately 24 months) ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of South Florida, | Tampa | Florida | 33612 | - |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19017 | - |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | - |
| Tennessee Oncology | Nashville | Tennessee | 37203 | - |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | - |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Tampa, FL
By condition
By specialty
Related Studies
- Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk WomenRecruiting · M.D. Anderson Cancer Center · Miami, Florida
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian CancerRecruiting · NRG Oncology · Birmingham, Alabama